MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaa1905

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021

The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali.

Phiri Mphatso Dennis, Cairns Matthew, Zongo Issaka, Nikiema Frederic, Diarra Modibo, Yerbanga Rakiswendé Serge, Barry Amadou, Tapily Amadou, Coumare Samba, Thera Ismaila, Kuepfer Irene, Milligan Paul, Tinto Halidou, Dicko Alassane, Ouédraogo Jean Bosco, Greenwood Brian, Chandramohan Daniel, Sagara Issaka

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Mass drug administration (MDA) with azithromycin (AZ) is being considered as a strategy to promote child survival in sub-Saharan Africa, but the mechanism by which AZ reduces mortality is unclear. To better understand the nature and extent of protection provided by AZ, we explored the profile of protection by time since administration, using data from a household-randomized, placebo-controlled trial in Burkina Faso and Mali.

METHODS

Between 2014 and 2016, 30 977 children aged 3-59 months received seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine and either AZ or placebo monthly, on 4 occasions each year. Poisson regression with gamma-distributed random effects, accounting for the household randomization and within-individual clustering of illness episodes, was used to compare incidence of prespecified outcomes between SMC+AZ versus SMC+placebo groups in fixed time strata post-treatment. The likelihood ratio test was used to assess evidence for a time-treatment group interaction.

RESULTS

Relative to SMC+placebo, there was no evidence of protection from SMC+AZ against hospital admissions and deaths. Additional protection from SMC+AZ against malaria was confined to the first 2 weeks post-administration (protective efficacy (PE): 24.2% [95% CI: 17.8%, 30.1%]). Gastroenteritis and pneumonia were reduced by 29.9% [21.7; 37.3%], and 34.3% [14.9; 49.3%], respectively, in the first 2 weeks postadministration. Protection against nonmalaria fevers with a skin condition persisted up to 28 days: PE: 46.3% [35.1; 55.6%].

CONCLUSIONS

The benefits of AZ-MDA are broad-ranging but short-lived. To maximize impact, timing of AZ-MDA must address the challenge of targeting asynchronous morbidity and mortality peaks from different causes.

Для цитирования: Phiri Mphatso Dennis, Cairns Matthew, Zongo Issaka, Nikiema Frederic, Diarra Modibo, Yerbanga Rakiswendé Serge, Barry Amadou, Tapily Amadou, Coumare Samba, Thera Ismaila, Kuepfer Irene, Milligan Paul, Tinto Halidou, Dicko Alassane, Ouédraogo Jean Bosco, Greenwood Brian, Chandramohan Daniel, Sagara Issaka. The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021. DOI: 10.1093/cid/ciaa1905.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.